Bitter pill for pharma: Govt pushes for compulsory licenses

The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18's Archana Shukla.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney SME Special
moneycontrol.com

Home » News » CNBC-TV18 Comments

Jan 27, 2013, 11.51 AM | Source: CNBC-TV18

Bitter pill for pharma: Govt pushes for compulsory licenses

The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18's Archana Shukla.

Like this story, share it with millions of investors on M3

Bitter pill for pharma: Govt pushes for compulsory licenses

The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18's Archana Shukla.

Post Your Comments

Share Cancel

The government has signaled its hard stance on invoking more compulsory licenses, this with the department of industrial policy and promotion (DIPP) listing three anti-cancer drugs as next compulsory licensing candidates. The industry has mixed views on it, reports CNBC-TV18’s Archana Shukla.

The issue relating to saving and securing intellectual property rights (IPR) by the multi-nationals is one critical concern, but experts and industry views are also questioning the provisions under which compulsory licensing would be given especially for complex biotech drugs.

Three drugs are part of this list right now - Roche's breast cancer drug, Herceptin, which is a biotech drug. Bristol-Myers Squibb's (BMS’s) Leukemia drug Sprycel and BMS’s other breast cancer drug Ixempra.

Herceptin is a difficult biotech drug and industry views suggest that it would be very difficult for a generic company to manufacture a generic version of Herceptin in less than two-three years time because lot of bio-equivalent studies have to be done to make the drug look like the original patented drug. Besides that, in India we do not have a clear protocol of how to approve a generic biotech drug. That is where this entire process will get stalled is what the industry says.

Secondly, Natco has already launched almost 94 percent cheaper version in the market for Dasatinib, so affordability has been taken care when it comes to the Leukemia drug Sprycel. Roche last year had launched an almost 33 percent cheaper version of Herceptin in the market.

They were pre-empting that possibly a compulsory licence could be issued on Herceptin because it is an important drug. It treats Breast Cancer so they had brought down the prices and that is where some critics say that Roche will have a stronger case when it comes to compulsory licence.

The provision under which government is planning to give compulsory licence is section 92 of the Indian Patent Act, which allows them to unilaterally grant a compulsory licence if they find that a drug is unaffordable, unaccessible or is not supplied enough.

The other section of the industry is pushing for a compulsory license. They are saying that this will be dealt with; we need more data to see if these are the correct candidates, but we have to make a beginning somewhere and when it comes to affordability, compulsory license will be one key element to be used.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Bitter pill for pharma: Govt pushes for compulsory licenses

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login